A new biomarker of cardiac resynchronization therapy response: cGMP to mature BNP ratio. Issue 6 (June 2022)

• Record Type: Journal Article
• Authors: Yokoyama, Yasuhiro; Kataoka, Naoya; Nakai, Michikazu; Matsuo, Ayaka; Fujiwara, Akihiro; Wakamiya, Akinori; Ueda, Nobuhiko; Nakajima, Kenzaburo; Kamakura, Tsukasa; Wada, Mitsuru; Yamagata, Kenichiro; Ishibashi, Kohei; Inoue, Yuko; Miyamoto, Koji; Nagase, Satoshi; Noda, Takashi; Aiba, Takeshi; Takahama, Hiroyuki; Izumi, Chisato; Kinugawa, Koichiro; Minamino, Naoto; Kusano, Kengo
• Is Part Of: Journal of cardiology. Volume 79:Issue 6(2022)
• Page Start: 727
• Page End: 733
• Publication Date: 2022-06
• Subjects: Heart failure -- Cardiac resynchronization therapy -- Brain/B-type natriuretic peptide; Cardiology -- Periodicals; 616.12
• DOI: 10.1016/j.jjcc.2021.12.015
• Languages: English
• ISSNs: 0914-5087

Abstract

Highlights: Previous studies have failed to reveal the predictive power of brain/B-type natriuretic peptide (BNP) for cardiac resynchronization therapy (CRT) response. BNP comprises mature BNP with full bioactivity and proBNP with 15% activity. We can calculate total BNP, proBNP, and estimated mature BNP (emBNP) by using two BNP kits. Each BNP form along with cyclic guanosine monophosphate (cGMP) was assessed to predict CRT response. The cGMP to emBNP ratio was found to be a promising predictor of CRT responders. Abstract: Background: Biomarkers that can predict cardiac resynchronization therapy (CRT) response have not yet been identified. The purpose of this study was to assess whether individual measurements of four brain/B-type natriuretic peptide (BNP) forms, coupled with cyclic guanosine monophosphate (cGMP) might contribute to the prediction of echocardiographic CRT responders. Methods: A BNP precursor (proBNP) and total BNP (= proBNP + mature BNP) were measured with newly developed kits, while an N-terminal fragment of proBNP (NT-proBNP) and cGMP were measured with commercial kits on the day before CRT implantation. Estimated mature BNP (emBNP = total BNP–proBNP), and the ratio of cGMP to each BNP form, as well as the concentrations of three other BNP forms, were prospectively investigated for their capability in predicting a response to CRT. A CRT responder was defined as an improvement in left ventricular ejection fraction >10% and/or a reduction in left ventricular end-systolic volume >15% at 6-month follow-up. Results: Out of 77 patients, 46 (60%) were categorized as CRT responders. Among the measurement parameters, only the highest quartile of the cGMP to emBNP ratio was an independent predictor of CRT responders (odds ratio 4.87, 95% confidence interval 1.25-18.89, p = 0.02). The cGMP to emBNP ratio was associated with the cumulative events of heart failure hospitalization within one year following CRT implantation (log-rank p = 0.029). Conclusions: The cGMP to emBNP ratio could be utilized as a predictive biomarker of CRT responders. (Clinical Study on Responder Prediction in Cardiac Resynchronization Therapy Using Individual Molecular Measurement of Natriuretic Peptide: UMIN R000038927). Graphical abstract: Image, graphical abstract